Loading...
Market
Will Gilead Sciences reduce the price of lenacapavir to $40 or less annually by end of 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Official press release from Gilead Sciences or reputable news sources
Story
Gilead HIV Treatment Could Be Made for $26 to $40 Annually, 1,000 Times Cheaper
Jul 23, 2024, 01:25 PM
A new analysis reveals that a Gilead Sciences HIV treatment, lenacapavir, could be produced for as little as $26 to $40 per person each year, significantly lower than its current price of over $40,000. Researchers highlight that this 'vaccine-like' drug has the potential to both prevent and suppress HIV, offering a groundbreaking advancement in HIV treatment. The cost reduction, which equates to approximately Ksh. 5280 and makes the treatment 1,000 times cheaper, could make the treatment accessible to a broader population, potentially revolutionizing HIV care globally.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Uniform pricing across all markets • 25%
Tiered pricing based on market income levels • 25%
Significant discounts in low-income countries • 25%
Other pricing strategy • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Below $10,000 per year • 25%
$10,000 - $20,000 per year • 25%
$20,000 - $30,000 per year • 25%
Above $30,000 per year • 25%
